A Phase II, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients Newly Diagnosed with Type 2 Diabetes Mellitus

Table 1

Demographics and baseline characteristics of the study population (N = 198).

	Metformin Arm 1 (N = 64)	Low-dose NW Low-Glu® Arm 2 (N = 65)	High-dose NW Low-Glu® Arm 3 (N = 69)
Characteristic
Age (yrs), median (IQR)	49 (16)	50 (14)	39 (13.5)
BMI (kg/m^2), mean ± SD	33.1 ± 3.8	31.5 ± 3.9	31.6 ± 4.2
SBP (mmHg), mean ± SD	124.6 ± 10.4	124.2 ± 13.4	123.1 ± 12.02
DBP (mmHg), mean ± SD	78.9 ± 6.2	77.9 ± 7.9	77.4 ± 6.9
Diabetes duration (months), mean ± SD	7.1 ± 9.9	6.3 ± 9.5	6.8 ± 10.1
Smoking duration (yrs), mean ± SD	18.5 ± 8.7	21.8 ± 12.1	25.2 ± 9.6
Gender, no. (%)
Females	41 (64.1)	33 (50.8)	37 (53.8)
Males	23 (35.9)	32 (49.2)	32 (46.4)
Marital status, no. (%)
Single	0	2 (3.1)	0
Married	59 (92.2)	60 (92.3)	66 (95.7)
Widow	3 (4.7)	2 (3.1)	2 (2.9)
Divorced	2 (3.1)	1 (1.5)	1 (1.4)
Education, no. (%)
None	7 (10.9)	4 (6.2)	1 (1.4)
Basic/primary	11 (17.2)	8 (12.3)	14 (20.3)
Secondary	37 (57.8)	35 (53.8)	41 (59.4)
Graduate or higher	9 (14.1)	18 (27.7)	13 (18.8)
Employment, no. (%)
Unemployed	25 (39.1)	21 (32.3)	23 (33.3)
Employed	33 (51.6)	39 (60.0)	44 (63.8)
Retired	6 (9.4)	5 (7.7)	2 (2.9)
Residence, no. (%)
Urban	56 (87.5)	59 (90.8)	62 (89.9)
Rural	8 (12.5)	6 (9.2)	7 (10.1)
Physical examination, no. (%)
Normal	64 (100)	65 (100)	69 (100)
Abnormal	0	0	0
Family history of diabetes
no. (%)	41 (64.1)	40 (61.5)	45 (65.2)
Smoking habits, no. (%)
Never	53 (82.8)	52 (80.0)	58 (84.1)
Former	3 (4.7)	3 (4.6)	0
Current	8 (12.5)	10 (15.4)	11 (15.9)